| Quarterly Financials | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 622 | 572 | 573 | 547 | 579 | 503 | 526 | 529 |
| Expenses | 368 | 393 | 377 | 370 | 400 | 367 | 404 | 397 |
| EBITDA | 254 | 179 | 195 | 177 | 179 | 137 | 122 | 132 |
| Operating Profit % | 29 % | 24 % | 23 % | 21 % | 22 % | 21 % | 23 % | 23 % |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 10 |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 244 | 169 | 186 | 167 | 169 | 127 | 113 | 122 |
| Tax | 54 | 46 | 34 | 30 | 33 | 24 | 30 | 31 |
| Net Profit | 190 | 123 | 152 | 138 | 137 | 103 | 82 | 91 |
| EPS in ₹ | 82.78 | 53.37 | 65.95 | 59.79 | 59.31 | 44.81 | 35.69 | 39.64 |
Sanofi
5,730.00
-25.00
(-0.43%)
Market Cap
13,196.55 Cr
EPS
179.46
PE Ratio
29.98
Dividend Yield
2.03 %
Industry
Healthcare52 Week High
10,524.95
52 Week Low
4,902.00
PB Ratio
15.40
Debt to Equity
0.02
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,733.80 | #1 4,15,996.70 | 35.93 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 50.33 | |
5,951.00 | 1,57,980.35 | 76.53 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 52.20 | |
1,473.80 | 1,19,026.29 | 24.07 | 26,520.70 | 14.17 | 4,155 | 47.38 | 46.85 | |
3,123.70 | 1,05,720.20 | 57.85 | 10,785.70 | 11.59 | 1,656 | 13.54 | 44.66 | |
2,374.00 | 97,946.14 | 49.19 | 10,615.60 | 19.57 | 1,942 | -16.38 | 49.28 | |
1,147.50 | 95,753.75 | #1 17.85 | 28,905.40 | 12.36 | 5,578 | 1.69 | 45.30 | |
2,007.60 | 91,655.16 | 32.06 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 47.99 | |
873.75 | 87,919.69 | 19.35 | 19,831.50 | 13.82 | 3,831 | 29.92 | 48.40 | |
1,145.00 | 66,501.79 | 19.08 | 29,559.20 | 17.55 | 3,169 | -10.04 | 46.30 | |
29,905.00 | 63,546.04 | 47.81 | 6,097.20 | 10.80 | 1,201 | 16.01 | 48.10 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-1.34 %
Net Income Growth
-13.96 %
Cash Flow Change
100.30 %
ROE
1.50 %
ROCE
-2.71 %
EBITDA Margin (Avg.)
-
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2023 | 2024 |
| Total Assets | 1,715 | 1,612 |
| Fixed Assets | 315 | 313 |
| Current Assets | 1,248 | 1,127 |
| Capital Work in Progress | 16 | 18 |
| Investments | 0 | 0 |
| Other Assets | 1,384 | 1,281 |
| Total Liabilities | 1,715 | 1,612 |
| Current Liabilities | 651 | 719 |
| Non Current Liabilities | 48 | 32 |
| Total Equity | 1,015 | 861 |
| Reserve & Surplus | 992 | 838 |
| Share Capital | 23 | 23 |
Cash Flow
| Cash Flow | 2023 | 2024 |
| Net Cash Flow | -610 | -111 |
| Investing Activities | 38 | -180 |
| Operating Activities | 230 | 462 |
| Financing Activities | -878 | -392 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % | 60.40 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 6.80 % | 0.00 % | 6.11 % | 5.81 % | 5.78 % | 5.63 % | 5.57 % |
| DIIs | 17.16 % | 17.39 % | 17.65 % | 19.03 % | 18.65 % | 18.60 % | 18.27 % | 19.21 % | 19.47 % | 19.66 % | 21.69 % | 22.47 % | 23.08 % | 22.79 % | 22.82 % | 22.93 % | 23.02 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.97 % | 7.09 % | 7.21 % | 7.01 % | 7.65 % | 7.92 % | 8.81 % | 9.13 % | 9.29 % | 8.89 % | 8.60 % | 8.09 % | 7.97 % | 8.31 % | 8.21 % | 8.33 % | 8.38 % |
| Others | 15.48 % | 15.12 % | 14.74 % | 13.56 % | 13.30 % | 13.09 % | 12.53 % | 11.26 % | 10.85 % | 11.05 % | 2.51 % | 9.04 % | 2.44 % | 2.69 % | 2.79 % | 2.70 % | 2.63 % |
| No of Share Holders | 0 | 48,465 | 53,567 | 51,646 | 50,916 | 59,276 | 64,542 | 73,734 | 76,694 | 71,513 | 68,598 | 62,870 | 61,849 | 67,662 | 66,211 | 66,401 | 68,196 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 71 | 84 | 349 | 365 | 490 | 570 | 167 | 117 | 0.00 |
| Dividend Yield (%) | 0.00 | 1.37 | 1.44 | 5.58 | 4.63 | 6.53 | 10.15 | 2.06 | 2.04 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 15 May 2025 |  Annual General Meeting | NA | 15 May 2025 | 5,568.15 | 5,754.70 |
| 25 Apr 2025 |  Dividend | ₹ 117.00 /share | 25 Apr 2025 | 5,059.65 | 6,570.50 |
| 27 Feb 2025 |  Quarterly Result Announcement | NA | 27 Feb 2025 | 5,358.40 | 5,059.65 |
| 07 Nov 2024 | Quarterly Result Announcement | NA | 07 Nov 2024 | 7,024.25 | 6,583.05 |
| 14 May 2024 | Annual General Meeting | NA | 14 May 2024 | 9,208.85 | 7,995.05 |
| 03 May 2024 | Dividend | ₹ 117.00 /share | 03 May 2024 | 9,208.85 | 8,679.45 |
| 07 Mar 2024 | Dividend | ₹ 50.00 /share | 07 Mar 2024 | 9,208.85 | 8,529.75 |
| 18 Dec 2023 |  Extraordinary General Meeting | NA | 18 Dec 2023 | 7,804.20 | 8,054.90 |
| 11 May 2023 | Annual General Meeting | NA | 11 May 2023 | 5,399.30 | 5,700.45 |
| 29 Apr 2023 | Dividend | ₹ 183.00 /share | 28 Apr 2023 | 5,399.30 | 5,572.25 |
| 29 Apr 2023 | Dividend | ₹ 194.00 /share | 28 Apr 2023 | 5,399.30 | 5,572.25 |
| 08 Aug 2022 | Dividend | ₹ 193.00 /share | 05 Aug 2022 | 6,749.00 | 6,542.60 |
| 26 Apr 2022 | Annual General Meeting | NA | 26 Apr 2022 | 7,136.45 | 6,979.40 |
| 16 Apr 2022 | Dividend | ₹ 309.00 /share | 12 Apr 2022 | 7,136.45 | 7,300.40 |
| 16 Apr 2022 | Dividend | ₹ 181.00 /share | 12 Apr 2022 | 7,136.45 | 7,300.40 |
| 21 Apr 2021 | Dividend | ₹ 125.00 /share | 19 Apr 2021 | 7,919.85 | 7,682.05 |
| 21 Apr 2021 | Dividend | ₹ 240.00 /share | 19 Apr 2021 | 7,919.85 | 7,682.05 |
Announcements
Announcement under Regulation 30 (LODR)-Change in Management
2 days ago
2 days agoDisclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 25, 2025
Apr 25, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 24, 2025
Apr 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 23, 2025
Apr 23, 2025Business Responsibility and Sustainability Reporting (BRSR)Apr 22, 2025
Apr 22, 2025Notice Of The Sixty Ninth Annual General MeetingApr 22, 2025
Apr 22, 2025Reg. 34 (1) Annual Report.Apr 22, 2025
Apr 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 16, 2025
Apr 16, 2025Rumour verification - Regulation 30(11)Apr 15, 2025
Apr 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Apr 09, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateApr 09, 2025
Apr 09, 2025Announcement under Regulation 30 (LODR)-Resignation of Managing DirectorApr 09, 2025
Apr 09, 2025Closure of Trading WindowApr 04, 2025
Apr 04, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 02, 2025
Apr 02, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMar 18, 2025
Mar 18, 2025Record Date For Final Dividend For The Financial Year Ended 31St December 2024Mar 18, 2025
Mar 18, 2025Board Meeting Outcome for Outcome Of The Meeting Of The Board Held On 18Th March 2025Mar 18, 2025
Mar 18, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 13, 2025
Mar 13, 2025Announcement Under Regulation 30 (LODR)-Newspaper PublicationMar 12, 2025
Mar 12, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 03, 2025
Mar 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 01, 2025
Mar 01, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceFeb 28, 2025
Feb 28, 2025Integrated Filing (Financial)Feb 28, 2025
Feb 28, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 28, 2025
Feb 28, 2025Announcement under Regulation 30 (LODR)-Dividend UpdatesFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 27, 2025
Feb 27, 2025Financial Results For The Financial Year Ended 31St December 2024Feb 27, 2025
Feb 27, 2025Board Meeting Outcome for Board Meeting Outcome For Standalone And Consolidated Financial Results For The Quarter And Year Ended 31St December 2024 And Recommendation Of Final DividendFeb 27, 2025
Feb 27, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 22, 2025
Feb 22, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 21, 2025
Feb 21, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 19, 2025
Feb 19, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 18, 2025
Feb 18, 2025Board Meeting Intimation for Consideration And Approval Of The Audited Financial Statements (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St December 2024 And Recommendation OFeb 13, 2025
Feb 13, 2025Appointment of Company Secretary and Compliance OfficerFeb 11, 2025
Feb 11, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 05, 2025
Feb 05, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 22, 2025
Jan 22, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 08, 2025
Jan 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2025
Jan 06, 2025Change Of Name Of Registrar And Transfer Agent Of The CompanyJan 02, 2025
Jan 02, 2025Closure of Trading WindowDec 27, 2024
Dec 27, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 09, 2024
Dec 09, 2024Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Nov 27, 2024
Nov 27, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 25, 2024
Nov 25, 2024Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Nov 13, 2024
Nov 13, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 13, 2024
Nov 13, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Nov 08, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 08, 2024
Nov 08, 2024Announcement Under Reg. 30Nov 07, 2024
Nov 07, 2024Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended30Th September 2024Nov 07, 2024
Nov 07, 2024Technical Indicators
RSI(14)
Neutral 39.95
ATR(14)
Volatile 168.83
STOCH(9,6)
Oversold 5.97
STOCH RSI(14)
Oversold 0.00
MACD(12,26)
Bearish -79.44
ADX(14)
Weak Trend 21.87
UO(9)
Bearish 39.17
ROC(12)
Downtrend And Accelerating -8.74
WillR(14)
Oversold -95.77
About Sanofi
Sanofi India Limited is a pharmaceutical company primarily engaged in manufacturing and trading drugs and pharmaceuticals. It operates manufacturing facilities in Goa and Ankleshwar, Gujarat, and sells products through independent distributors mainly in India. The company focuses on five therapeutic areas: diabetes, epilepsy, cardiology, allergy, and pain care. Key products include Lantus (insulin), Combiflam (pain relief), Amaryl (anti-diabetic), Allegra (allergy), Cardace (cardiovascular), and Toujeo (long-acting insulin). Sanofi India is majority-owned by Sanofi and its subsidiary Hoechst GmbH, holding 60.37% of its paid-up share capital. The company has undergone several name changes and acquisitions, including the purchase of Universal Medicare's nutraceutical business in 2011. In 2021, Sanofi India sold its Nutraceuticals business to Universal Nutriscience Private Limited, and in 2022-23, its Consumer Healthcare Business was demerged into a wholly-owned subsidiary.
Chairperson NameAditya Narayan
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
